Results of preimplantation screening offer new hope for treatment of recurrent miscarriage
BlueGnome21 April 2011
Results of preimplantation screening offer new hope for treatment of recurrent miscarriage.
Preliminary study published in Human Reproduction reports over 70% clinical pregnancy rate in a previously challenging cohort.
A new publication by Francesco Fiorentino1 at Genoma in Rome presents the first results of a preimplantation genetic screening study in cases of recurrent miscarriage arising from balanced translocations in one or both parents. Balanced translocations are carried by up to 1 in 500 of the general population. In such cases the carrier parent is typically unaffected however the underlying genetic aberrations can result in embryos with large structural imbalances which are seldom viable and frequently end in miscarriage.
The team at Genoma used BlueGnome’s 24sure+ platform to screen 228 embryos from 28 affected couples undergoing IVF treatment. The paper reports that 24sure+ gave results on 93% of the samples tested but that only 16% of these were genetically normal. As a result viable embryos were identified in over 60% of the couples. Most encouraging, over 70% of the embryos transferred in these cases went on to form successful pregnancies, more than double the rate that was reported using earlier, FISH based, techniques.
Commenting on the paper Dr Dagan Wells of Oxford University, who uses the same 24sure+ platform at Reprogenetics UK, said, “Our intuition has always been that the underlying fertility of couples with balanced translocations should be very good and that if we could reliably identify and transfer a normal embryo we could expect a very good outcome. The results from Genoma in Rome are consistent with this hypothesis and indeed our own experience at Reprogenetics”. Dr Wells has also recently published data using BlueGnome microarrays to screen embryos from carriers of chromosome rearrangements. His findings from patients in the UK echo those of Dr Fiorentino, with only 22% of the embryos produced found to be chromosomally balanced2.
In addition to significant improvements in outcome Dr Fiorentino’s paper also reported that in this cohort, (mean maternal age of 37) over a quarter of the embryos were unaffected by imbalances inherited from the parents but were carrying whole chromosome imbalances more likely to be associated with high maternal age. The importance of this finding was stressed by the paper’s author. “We now appreciate the there is a real benefit in screening all chromosomes in these cases, something that is very straightforward with an approach like 24sure+”.
1 Fiorentino et al. Hum Reprod. 2011 Apr 12. [Epub ahead of print]
2 Alfarawati et al. Hum Reprod. 2011 Mar 29. [Epub ahead of print]
BlueGnome (www.24suretest.com) is a specialist developer of microarray based solutions for the screening of chromosomal abnormalities in cytogenetics and IVF.
BlueGnome microarrays are for research use only.
For further information please contact:
BlueGnome Ltd, Mill Court, Great Shelford, Cambridge, CB22 5LD, UK.
T: +44 1223 844441 F: +44 1223 844445 E: [email protected]
GENOMA (www.laboratoriogenoma.eu) is a private molecular genetics laboratory, internationally renowned for its leadership in molecular diagnostics and preimplantation genetic diagnosis (PGD) and for its pioneering work in infertility and genetics.
About Reprogenetics UK
Reprogenetics (www.reprogenetics.com) is a private genetics laboratory specializing in Preimplantation Genetic Diagnosis (PGD). Founders, Drs. Santiago Munné and Jacques Cohen, have been performing PGD since 1991. The Reprogenetics team services over 200 IVF groups worldwide and has performed >20,000 PGD cycles, 3,400 annually.
Cambridge, 20th November 2011